Skip to content Skip to footer

Loading Results

Hong Kong becoming a global hub for biotech and healthcare listing

3rd anniversary of HKEX's regime for biotech company listing
June 2021

HKEX launched the new listing regime on 30 April 2018 which included the new Chapter 18A of the Main Board Listing Rules allowing the listing of pre-revenue biotech companies that do not meet any of the Main Board financial eligibility requirements. Three years on, 32 companies have been listed raising a total of USD10.5b.

While HKEX is the world’s second biggest biotech fundraising hub, on the 3rd anniversary of HKEX’s regime for biotech company listing, PwC Hong Kong Capital Market Services Partner, Mr Edmond Chan has shared his thoughts on the growth and evolution of this new chapter and the market for listing of biotech companies in Hong Kong.

Playback of this video is not currently available

2:57

Hong Kong becoming a global hub for biotech and healthcare

Contact us

Edmond Chan

Edmond Chan

Partner, Co-Head of Capital Market Services, PwC Hong Kong

Tel: +[852] 2289 1128

Geoffrey Tang

Geoffrey Tang

Director, PwC Hong Kong

Tel: +[852] 2289 1886

Follow us